Ultra Market Research | United States Growth Hormone Deficiency Market
United States Growth Hormone Deficiency Market
Report ID : 1104
Category : United-States(US)
No Of Pages : 145
Published on: June 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The United States Growth Hormone Deficiency (GHD) market involves the diagnosis, treatment, and management of conditions resulting from inadequate production of growth hormones. GHD may occur in children and adults, which results in stunted growth, bone density reduction, and other metabolic problems. Therapeutic programs are mainly confined to recombinant human growth hormone (rhGH) therapies, which have undergone tremendous development over time. Recent trends have been towards long-acting preparations like Skytrofa and Ngenla that provide better patient compliance with less frequent administration. The U.S. market is expected to see high growth, with projected estimates of around USD 7.17 billion by 2034, led by innovation in drug delivery systems and the rising incidence of GHD.
Segmentation
Segment 1: Application
Pediatric GHD
Idiopathic Short Stature
Turner Syndrome
Small for Gestational Age
Prader-Willi Syndrome
Others
Adult GHD
Panhypopituitarism
Hypothalamic-Pituitary Dysfunction
Others
Others
Segment 2: Drug Type
Recombinant Human Growth Hormone (rhGH)
Somatropin
Somatrogon
Lonapegsomatropin
Others
Biosimilars
Omnitrope
Tev-Tropin
Others
Others
Segment 3: Route of Administration
Subcutaneous Injection
Daily
Weekly
Others
Oral
Oral Secretagogues
Others
Others
Segment 4: Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
Others
Segment 5: End-User
Hospitals
Clinics
Home Care Settings
Others
List of Market Players
Ascendis Pharma (Denmark)
Pfizer Inc. (USA)
Novo Nordisk A/S (Denmark)
Eli Lilly and Company (USA)
Merck & Co., Inc. (USA)
Ipsen S.A. (France)
Sandoz International GmbH (Switzerland)
Teva Pharmaceutical Industries Ltd. (Israel)
Mylan N.V. (USA)
Genexine, Inc. (South Korea)
Handok Inc. (South Korea)
Hikma Pharmaceuticals PLC (UK)
Ferring Pharmaceuticals (Switzerland)
Biocon Limited (India)
Lonza Group Ltd. (Switzerland)
Drivers
U.S. Growth Hormone Deficiency market is driven by the following factors:
Growing Prevalence: An increase in the rate of GHD cases, pediatric as well as adult, has increased the need for efficient treatments.
Advances in Drug Formulations: The creation of long-acting growth hormone drugs, e.g., weekly injections, has enhanced patient compliance and treatment outcomes.
Technology Advances: Introduction of digital health technologies such as telemedicine and remote monitoring has made it easier to manage GHD .
Increased Awareness and Early Diagnosis: Growing awareness and early screening campaigns have resulted in early diagnosis, allowing for immediate treatment initiation.
Positive Reimbursement Policies: Coverage by insurance companies for GHD treatments has increased, making the therapies more accessible to patients.
Restraints
Even though the market continues to grow, some challenges remain:
High Treatment Cost: The cost of GHD therapies, particularly long-acting drugs, might be out of reach for some patients.
Regulatory Barriers: Regulatory hurdles and strict FDA approval processes can set back the release of new treatments.
Side Effects: Side effects of growth hormone treatments, including swelling and pain in the joints, might discourage patient compliance.
Off-Label Use Issues: Off-label use of growth hormones for indications not approved by regulatory authorities, such as anti-aging, is both ethically and legally questionable
Market Competition: Having several biosimilars and generics in the market can cause price competition, which impacts margins.
Opportunity
The U.S. GHD market offers the following opportunities for growth:
Personalized Medicine: Progress in genetic testing makes possible customized treatment regimens, improving efficacy and patient satisfaction.
Emerging Markets: Forays into under-penetrated areas in the U.S. can expand market penetration.
Combination Therapies: Products combining multiple treatments can provide synergistic benefits, enhancing patient outcome.
Pediatric Focus: Emphasis on GHD in children can leverage an increasing patient population, given early intervention is key.
Digital Health Integration: Integrating digital monitoring and management tools can improve treatment adherence and patient involvement.
Trend
New trends in the U.S. GHD market are:
Long-Acting Formulations: Moving away from daily or more frequent dosing regimens has enhanced patient compliance and quality of life.
Oral Therapies: Oral growth hormone secretagogues under development provide an injection-free option, which is attractive for needle-phobic patients.
Digital Health Platforms: Telemedicine and mobile health apps enable remote monitoring and customized care.
Regenerative Medicine: Stem cell therapies and gene editing have potential for future GHD treatment.
Patient-Centric Approaches: Patient education and support programs prioritize patient safety, adherence to treatment, and promoting patient satisfaction.
Approved Products
Skytrofa (Lonapegsomatropin)
Ngenla (Somatrogon)
Sogroya (Somapacitan)
Humatrope (Somatropin)
Omnitrope (Somatropin)
Tev-Tropin (Somatropin)
Genotropin (Somatropin)
Norditropin (Somatropin)
Saizen (Somatropin)
Zomacton (Somatropin)
Nutropin (Somatropin)
Serostim (Somatropin)
Saizen (Somatropin)
Humatrop (Somatropin)
Eutropin (Somatropin)
Key Target Audience
Endocrinologists
Pediatricians
General Practitioners
Hospitals and Clinics
Pharmaceutical Companies
Biotechnology Firms
Regulatory Authorities
Healthcare Providers
Insurance Companies
Patients and Caregivers
The U.S. market is valued at approximately USD 2.17 billion in 2024 and is projected to reach around USD 7.17 billion by 2034 .
Key players include Ascendis Pharma, Pfizer Inc., Novo Nordisk A/S, and Eli Lilly and Company.
Treatment options include recombinant human growth hormones like Skytrofa, Ngenla, and Sogroya.
The introduction of long-acting formulations and oral therapies has improved patient adherence and convenience.
The market is expected to grow due to advancements in personalized medicine, digital health integration, and emerging therapies
1. Introduction
1.1 Report Description
1.2 Research Methodology
1.2.1 Data Mining
1.2.2 Market Modeling and Forecasting
1.2.3 Data Validation
1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview
3.1 Market Definition and Scope
3.2 Market Segmentation
3.2.1 By Treatment Types
3.2.2 By Patient Demographics
3.2.3 By Distribution Channels
3.2.4 By Therapeutic Applications
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.3.4 Challenges
4. United States Growth Hormone Deficiency Therapeutics Market by Treatment Types
4.1 Introduction
4.2 Market Size and Growth Rate by Treatment Types (2024–2030)
4.2.1 Chemotherapy
4.2.1.1 Induction Phase
4.2.1.2 Consolidation Phase
4.2.1.3 Maintenance Phase
4.2.2 Targeted Therapies
4.2.2.1 Tyrosine Kinase Inhibitors
4.2.2.2 Antibody-Drug Conjugates
4.2.2.3 Others
4.2.3 Immunotherapies
4.2.3.1 CAR-T Therapy
4.2.3.2 Monoclonal Antibodies
5. United States Growth Hormone Deficiency Therapeutics Market by Patient Demographics
5.1 Introduction
5.2 Market Size and Growth Rate by Patient Demographics (2024–2030)
5.2.1 Children
5.2.1.1 Infants
5.2.1.2 Toddlers and Young Children
5.2.2 Adults
5.2.2.1 Young Adults
5.2.2.2 Seniors
6. United States Growth Hormone Deficiency Therapeutics Market by Distribution Channels
6.1 Introduction
6.2 Market Size and Growth Rate by Distribution Channels (2024–2030)
6.2.1 Hospital Pharmacies
6.2.1.1 Tertiary Care Centers
6.2.1.2 Pediatric Oncology Units
6.2.2 Retail Pharmacies
6.2.2.1 Local Pharmacies
6.2.2.2 Chain Pharmacies
6.2.3 Online Pharmacies
7. United States Growth Hormone Deficiency Therapeutics Market by Therapeutic Applications
7.1 Introduction
7.2 Market Size and Growth Rate by Therapeutic Applications (2024–2030)
7.2.1 First-Line Treatment
7.2.1.1 Chemotherapy-Only Regimens
7.2.1.2 Targeted Therapies
7.2.2 Relapse or Refractory GHD
7.2.2.1 CAR-T Therapies
7.2.2.2 Experimental Treatments
8. Competitive Landscape
8.1 Company Profiles
8.1.1 Amgen Inc. (United States)
Business Overview
Product Portfolio
Strategic Developments
Financial Overview
8.1.2 Novartis AG (Switzerland)
8.1.3 Pfizer Inc. (United States)
8.1.4 Gilead Sciences (United States)
8.1.5 Kite Pharma (United States)
8.1.6 Takeda Pharmaceutical Company (Japan)
8.1.7 Bristol-Myers Squibb (United States)
8.1.8 Jazz Pharmaceuticals (Ireland)
8.1.9 AbbVie Inc. (United States)
8.1.10 Sanofi (France)
8.1.11 Autolus Therapeutics (United Kingdom)
8.1.12 Cellectis (France)
8.1.13 Allogene Therapeutics (United States)
8.1.14 Celgene Corporation (United States)
8.1.15 Eli Lilly and Company (United States)
9. Conclusion and Strategic Recommendations
10. Appendix
10.1 List of Tables
Table United States Growth Hormone Deficiency Therapeutics Market Size by Treatment Types (2024–2030)
Table Chemotherapy Market Size by Sub-type (2024–2030)
Table Targeted Therapies Market Size by Sub-type (2024–2030)
Table Immunotherapies Market Size by Sub-type (2024–2030)
Table United States Growth Hormone Deficiency Therapeutics Market Size by Patient Demographics (2024–2030)
Table Children Market Size by Sub-type (2024–2030)
Table Adults Market Size by Sub-type (2024–2030)
Table United States Growth Hormone Deficiency Therapeutics Market Size by Distribution Channels (2024–2030)
Table Hospital Pharmacies Market Size by Sub-type (2024–2030)
Table Retail Pharmacies Market Size by Sub-type (2024–2030)
Table United States Growth Hormone Deficiency Therapeutics Market Size by Therapeutic Applications (2024–2030)
Table First-Line Treatment Market Size by Sub-type (2024–2030)
Table Relapse or Refractory GHD Market Size by Sub-type (2024–2030)
Tables Financial Overview of Key Companies
10.2 List of Figures
Figure United States Growth Hormone Deficiency Therapeutics Market Size and Growth Rate by Treatment Types (2024–2030)
Figure Chemotherapy Market Growth Rate by Sub-type (2024–2030)
Figure Targeted Therapies Market Growth Rate by Sub-type (2024–2030)
Figure Immunotherapies Market Growth Rate by Sub-type (2024–2030)
Figure United States Growth Hormone Deficiency Therapeutics Market Size and Growth Rate by Patient Demographics (2024–2030)
Figure Children Market Growth Rate by Sub-type (2024–2030)
Figure Adults Market Growth Rate by Sub-type (2024–2030)
Figure United States Growth Hormone Deficiency Therapeutics Market Size and Growth Rate by Distribution Channels (2024–2030)
Figure Hospital Pharmacies Market Growth Rate by Sub-type (2024–2030)
Figure Retail Pharmacies Market Growth Rate by Sub-type (2024–2030)
Figure United States Growth Hormone Deficiency Therapeutics Market Size and Growth Rate by Therapeutic Applications (2024–2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Growth Hormone Deficiency Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of CANOMAD syndrome Market for the past year and forecasts for the next six years. United States Growth Hormone Deficiency Marketsize is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Growth Hormone Deficiency Marketcategories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States Growth Hormone Deficiency Marketfrom different application industries in different regions.
